Immutep completes patient enrolment for Phase II trial of eftilagimod alpha in metastatic breast cancer

Pallavi Madhiraju- October 6, 2024 0

Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment for its Phase II AIPAC-003 clinical trial. ... Read More

Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment

Pallavi Madhiraju- July 20, 2024 0

Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application ... Read More

G1 Therapeutics’ Phase 3 trial of trilaciclib for metastatic triple negative breast cancer continues as planned

Pallavi Madhiraju- February 13, 2024 0

In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in cancer treatment, announced the continuation of its ... Read More

Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules

Pallavi Madhiraju- December 17, 2023 0

Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) ... Read More

Menarini’s EMERALD study of ORSERDU in breast cancer shows promising results

Pallavi Madhiraju- December 9, 2023 0

The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment with new findings from the pivotal EMERALD ... Read More

Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results

Pallavi Madhiraju- December 9, 2023 0

Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More

Exai Bio says novel RNA and AI-driven platform can detect early breast cancer

Pallavi Madhiraju- December 7, 2023 0

Exai Bio, a leader in healthcare innovation, announced groundbreaking data showcasing the efficacy of its novel RNA-based and AI-driven liquid biopsy platform in detecting breast ... Read More

Roche’s inavolisib meets primary endpoint of PFS in Phase 3 breast cancer trial

Pallavi Madhiraju- December 6, 2023 0

Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) ... Read More

FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment

Pallavi Madhiraju- November 20, 2023 0

In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More

Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients

Pallavi Madhiraju- July 27, 2023 0

In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences' Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering ... Read More